HippoFi and Zimmer Biomet are partnering to develop and launch a novel synthetic biomaterial for bone growth.
HippoFi and its subsidiary PUR Biologics have FDA 510(k) clearance for ActiveOrb technology and a global license from Zimmer Biomet to use in the spine market, according to a Sept. 7 news release. The companies are working under a joint commercialization research agreement to produce spine-specific products.
The synthetic biomaterial is expected to launch in 2024.
Lenoss Medical’s OsteoPearl procedure reached its 150th case, according to a March 27 news release shared with Becker’s. More than…
From new partnerships to product launches, here are 12 key developments in orthobiologics during the first quarter of 2025. 1.…
Miach Orthopaedics' BEAR (bridge-enhanced ACL restoration) implant is now available to treat children and adolescents with anterior cruciate ligament tears…
Comments are closed.